484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

484.85

+0.36%↑

SANES

10.518

+1.86%↑

SAF

313.7

-0.7%↓

BBVA

19.715

+2.6%↑

BNP

90.65

+1.55%↑

Kodu・Aktsiate loetelu・AB Science SA

AB Science SA

Suletud

1.174 1.03

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.164

Max

1.21

Põhinäitajad
By Trading Economics
Sissetulek	-5.2M
Müük	515K
Kasumimarginaal	-1,005.243
Töötajad	36
EBITDA	-2.5M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	78M
Eelmine avamishind	0.14
Eelmine sulgemishind	1.174

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

1.426 / 1.448 Toetus ja vastupanu

AB Science SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 17:04 UTC

Suurimad hinnamuutused turgudel

FDA Rejects Replimune's Melanoma Drug for a Second Time

11. apr 2026, 00:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Big Yachts, Big Bucks -- Barrons.com

10. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. apr 2026, 21:01 UTC

Tulu

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10. apr 2026, 18:25 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Finish With Weekly Gains -- Market Talk

10. apr 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10. apr 2026, 17:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10. apr 2026, 17:26 UTC

Tulu

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10. apr 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10. apr 2026, 17:00 UTC

Uudisväärsed sündmused

Construction Business Taking a Hit From Iran Conflict -- WSJ

10. apr 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10. apr 2026, 16:12 UTC

Tulu

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10. apr 2026, 16:11 UTC

Tulu

Partners Group: Traditional Programs Contributed $3.3B

10. apr 2026, 16:10 UTC

Tulu

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10. apr 2026, 16:10 UTC

Tulu

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10. apr 2026, 16:10 UTC

Tulu

Partners Group 1Q New Client Demand $8.3B

10. apr 2026, 16:09 UTC

Tulu

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10. apr 2026, 15:54 UTC

Omandamised, ülevõtmised, äriostud

Plenitude Completes Acquisition of Acea Energia

10. apr 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

AB Science SA Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi AB Science SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.426 / 1.448Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.